Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Verisign, Inc. (VRSN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Verisign, Inc. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.84 (market cap $4.49B), while Verisign, Inc. trades at $267.41 (market cap $24.28B). The key difference: Verisign, Inc. is far larger — about 5.4× ACADIA Pharmaceuticals Inc.'s market cap, and Verisign, Inc. pays a 1.21% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | VRSN | |
|---|---|---|
Market Cap | $4.49B | $24.28B |
Sector | Health | Technology |
52-Week High | $28.06 | $310.00 |
52-Week Low | $20.06 | $211.49 |
Enterprise Value | $3.69B | $25.52B |
Dividend Yield | — | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
VeriSign (VRSN) trades at $266.78, up 4.04% on the day, with a bearish technical signal and mixed earnings history including a Q1 2026 beat. The stock shows strong fundamentals with 49.96% net income margin and $825.7M net income for 2025, though negative shareholder equity remains a concern. Recent news highlights AI-driven domain growth and upcoming Q2 2026 earnings.
Outlook is cautiously optimistic with 57% analyst buy ratings and a $327.67 consensus target offering 23% upside. Key risks include contract renewals, AI disruption potential, and high debt levels. Revenue growth stability and margin strength support investment case, but technical resistance near $266 requires monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
